+

WO2002006343A3 - Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau - Google Patents

Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau Download PDF

Info

Publication number
WO2002006343A3
WO2002006343A3 PCT/US2001/022976 US0122976W WO0206343A3 WO 2002006343 A3 WO2002006343 A3 WO 2002006343A3 US 0122976 W US0122976 W US 0122976W WO 0206343 A3 WO0206343 A3 WO 0206343A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
treatment
tau
interferon
virus
Prior art date
Application number
PCT/US2001/022976
Other languages
French (fr)
Other versions
WO2002006343A2 (en
Inventor
Yoshihiro Sokawa
Chih-Ping Liu
Original Assignee
Pepgen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2000317160A external-priority patent/JP2006213597A/en
Application filed by Pepgen Corp filed Critical Pepgen Corp
Priority to EP01954835A priority Critical patent/EP1355938A2/en
Priority to AU2001277055A priority patent/AU2001277055A1/en
Publication of WO2002006343A2 publication Critical patent/WO2002006343A2/en
Publication of WO2002006343A3 publication Critical patent/WO2002006343A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of monitoring treatment of HCV by oral administration of ovine IFN-τ is disclosed. The method includes measuring the blood levels of 2', 5'-oligoadenylate synthetase prior to and after such oral administration, and if necessary, adjusting the dose of IFN-τ until a measurable increase in blood 2', 5'-oligoadenylate synthetase level, relative to the level observed prior to administration, is observed. Also disclosed are oral-delivery compositions for use in treating HCV in an HCV-infected patient comprising ovine IFN-τ, in a dosage effective to stimulate bloodstream levels of 2', 5'-oligoadenylate synthetase.
PCT/US2001/022976 2000-07-19 2001-07-19 Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau WO2002006343A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01954835A EP1355938A2 (en) 2000-07-19 2001-07-19 Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau
AU2001277055A AU2001277055A1 (en) 2000-07-19 2001-07-19 Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21912800P 2000-07-19 2000-07-19
US60/219,128 2000-07-19
JP2000317160A JP2006213597A (en) 2000-07-19 2000-10-17 Composition for treating hepatitis c virus by using interferon tau and method of monitoring
JP2000-317160 2000-10-17

Publications (2)

Publication Number Publication Date
WO2002006343A2 WO2002006343A2 (en) 2002-01-24
WO2002006343A3 true WO2002006343A3 (en) 2003-08-21

Family

ID=26602264

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/022976 WO2002006343A2 (en) 2000-07-19 2001-07-19 Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau

Country Status (3)

Country Link
EP (1) EP1355938A2 (en)
AU (1) AU2001277055A1 (en)
WO (1) WO2002006343A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105154B2 (en) 2000-07-19 2006-09-12 Pepgen Corporation Method of treatment using interferon-tau
US7431920B2 (en) 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
GB0208928D0 (en) * 2002-04-19 2002-05-29 Imp College Innovations Ltd Methods
US7354908B2 (en) 2002-04-30 2008-04-08 University Of South Florida Materials and methods for prevention and treatment of RNA viral diseases
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010313A2 (en) * 1992-10-30 1994-05-11 University Of Florida Interferon tau compositions and methods of use
WO1996035789A1 (en) * 1995-05-10 1996-11-14 The Women's Research Institute Human interferon tau compositions and methods of use
WO2000078266A2 (en) * 1999-06-22 2000-12-28 University Of Maryland College Park Interferon tau mutants and methods for making them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010313A2 (en) * 1992-10-30 1994-05-11 University Of Florida Interferon tau compositions and methods of use
WO1996035789A1 (en) * 1995-05-10 1996-11-14 The Women's Research Institute Human interferon tau compositions and methods of use
WO2000078266A2 (en) * 1999-06-22 2000-12-28 University Of Maryland College Park Interferon tau mutants and methods for making them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLAYETTE P ET AL: "[ IFN - tau, a new interferon type I with antiretroviral activity]. Un nouvel interferon de type I dote d'une activite antiretrovirale, L' IFN - tau.", PATHOLOGIE BIOLOGIE, (1999 MAY) 47 (5) 553-9., XP008009463 *
SAEZ-ROYUELA F ET AL: "TREATMENT OF CHRONIC NON-A NON-B HEPATITIS WITH HIGH DOSES OF RECOMBINANT IFN-ALPHA OR RECOMBINANT IFN - TAU.", 40TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES, CHICAGO, ILLINOIS, USA, OCTOBER 28-31, 1989. HEPATOLOGY (BALTIMORE). (1989) 10 (4), 646., XP008009464 *

Also Published As

Publication number Publication date
AU2001277055A1 (en) 2002-01-30
EP1355938A2 (en) 2003-10-29
WO2002006343A2 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
FI964593A0 (en) Oral liquid alendronate compositions
CA2594215A1 (en) Sustained-release nanoparticle compositions and methods for using the same
HK1050313A1 (en) Oral transmucosal drug dosage using solid solution
WO2002091997A3 (en) Oncolytic virus therapy
BRPI0108435B8 (en) formulation and use of low-dose entecavir
TR200402565T4 (en) Use of ß-L-2'-deoxy-nucleosides in the treatment of hepatitis delta virus infection
WO2001022934A3 (en) Delivery of small doses of ingestible treatments
IL171991A0 (en) Use of an interferon polypeptide in the preparation of a pharmaceutical composition for treating virus infection and a method of treating a virus-infected non human subject
MXPA03003445A (en) Herbal pharmaceutical composition for treatment of hiv/aids patients.
WO2005055955A3 (en) DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
WO2002006343A3 (en) Composition for treatment of and method of monitoring hepatitis c virus using interferon-tau
HK1041215A1 (en) Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection.
SE9902597D0 (en) New use
TW200517119A (en) Method of treatment using interferon-tau
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
WO2005013920A3 (en) Newcastle disease virus administration
EA200600757A1 (en) TETRAPEPTID REGULATING BLOOD GLUCOSE LEVEL DURING DIABETES MELLITUS
DE60125377D1 (en) TREATMENT OF HEPATITIS C WITH THYMOSINE, INTERFERON AND RIBAVIRIN
RU2005131943A (en) MEDICINAL AND / OR PREVENTIVE MEANS FOR CHRONIC SKIN DISEASES
RU2000108989A (en) METHOD FOR PREVENTION AND TREATMENT OF CAVIAR RESPIRATORY DISEASES
Yi et al. A case study of various clinical application of the rubber dam in pediatric dentistry
DE60020550D1 (en) METHOD AND MEANS FOR TREATING A POST POLIOSYNDROME
DE60121449D1 (en) TREATMENT OF HEPATITIS C WITH THYMOSINE AND PEGYLATED INTERFERON
WO2002072016A3 (en) Method of preventing adhesions with ifn-¿y?
TH70235A (en) Methods for treating hepatitis infection C. In patients whose treatment has failed.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001954835

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001954835

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载